You are here: Industry Insights > Seagen

News List

Seagen and RemeGen enter up to $2.6bn deal for cancer drug pharmaceutical-technology
August 11, 2021
Seagen and a Chinese company, RemeGen, have signed an exclusive global licencing agreement to develop and market a new HER2-targeted antibody-drug conjugate (ADC), disitamab vedotin.
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer americanpharmaceuticalreview
April 20, 2021
Astellas Pharma Inc. and Seagen Inc. announced the U.S. Food and Drug Administration (FDA) filed two supplemental Biologics License Application (sBLA) submissions for PADCEV® (enfortumab vedotin-ejfv) for review as part of the ...
EMA accepts Astellas/Seagen’s enfortumab vedotin for review pharmatimes
March 29, 2021
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Astellas and Seagen’s enfortumab vedotin.
Astellas, Seagen Submit sBLAs for PADCEV for Urothelial Cancer americanpharmaceuticalreview
February 24, 2021
Astellas Pharma and Seagen announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv).
Astellas, Seagen Announce PADCEV Trial Results for Urothelial Cancer americanpharmaceuticalreview
February 18, 2021
Astellas Pharma and Seagen announced primary results from the phase 3 EV-301 trial comparing PADCEV® (enfortumab vedotin-ejfv) to chemotherapy in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with ...
Astellas, Seagen Announce Positive Results from PADCEV Trial for Urothelial Cancer americanpharmaceuticalreview
October 16, 2020
Astellas Pharma and Seagen announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201.